Overview

This trial is active, not recruiting.

Conditions acute kidney injury, bacterial infection
Sponsor Heinrich-Heine University, Duesseldorf
Collaborator Fresenius Medical Care Deutschland GmbH
Start date September 2015
End date July 2016
Trial size 30 participants
Trial identifier NCT02533609, 2015-02-ENDVERSION

Summary

Acute kidney injury requiring renal replacement therapy is common in critically ill patients. The major causes of AKI are severe sepsis and septic shock requiring effective antibiotic treatment. Patients with sepsis on ICUs usually are haemodynamically instable so that renal replacement therapy is applied using continuous techniques. In recent years, the efficacy of renal replacement therapies has improved, namely by using regional citrate anticoagulation which improves filter lifetime and filter patency. At present, the extent of removal of antibiotic drugs using citrate-anticoagulated CVVHD in critically ill patients has not been investigated thoroughly. Thus, the investigators want to investigate

1. whether and to what extent antibiotic drugs (piperacillin/tazobactam and imipenem/cilastatin) are removed during citrate-anticoagulated CVVHD per se

2. whether filter patency during citrate-anticoagulated CVVD remains stable during a treatment period of 72 h

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Arm
Patients undergoing continuous veno-venous renal replacemtent therapy and treated with this antibiotics
Patients undergoing continuous veno-venous renal replacemtent therapy and treated with this antibiotics

Primary Outcomes

Measure
Removal of antibiotic drugs during day 1 - 2 - 3 of citrate anticoagulated CVVHD (mg/d)
time frame: up to three days
Filter patency during day 1 - 2 - 3 of citrate anticoagulated CVVHD
time frame: up to three days

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Intensive care patients with acute kidney injury requiring continous renal replacement therapy with citrate-anticoagulation - Age > 18 y Exclusion Criteria: - < 18 y - Pregnancy - Contraindications against citrate-anticoagulation or continous renal replacement therapy

Additional Information

Official title Elimination of Antibiotics During Citrate-anticoagulated Continuous-veno-venous-haemodialysis
Trial information was received from ClinicalTrials.gov and was last updated in February 2016.
Information provided to ClinicalTrials.gov by Heinrich-Heine University, Duesseldorf.